Publications
Healing and Maintenance of Healing of Erosive Esophagitis
Alimentary Pharmacology and Therapeutics – 2016
Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
Ashida K et al.
World Journal of Gastroenterology – 2018
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
Ashida K et al.
Gut – 2020
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
Xiao Y et al.
DDW– 2020
Tu1321 – Vonoprazan 10 or 20 mg demonstrated superiority over lanzoprazole 15 mg in preventing relapse in Asian patients with endoscopic healing of erosive esophagitis: A Phase 3, Randomized, Double-Blind, Multicenter Study
Xiao Y et al.
Eradication of H. pylori infection
Gut – 2016
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Murakami K et al.
Eradication of H. pylori infection
Gastroenterology – 2016
Tu1333 Dual Therapy With Vonoprazan and Amoxicillin Is as Effective as Standard PPI-Based Triple Therapy With Amoxicillin and Clarithromycin or Metronidazole in Japan
Furuta T et al.
Gastroenterology – 2018
Tu1299 – Vonoprazan-Based Dual Therapy with Amoxicillin is as Effective as the Triple Therapy for the Eradication of H. Pylori
Furuta T et al.
Gut – 2020
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
Suzuki S et al.
Erosive Esophagitis
Alimentary Pharmacology & Therapeutics – 2018
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis
Oshima T et al.
DDW– 2020
Tu1362 – 2-year interim analysis results of VISION TRIAL: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis
Uemura N et al.
Alimentary Pharmacology & Therapeutics – 2015
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
Jenkins H et al.
Alimentary Pharmacology & Therapeutics – 2015
Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study
Sakurai Y et al.
Alimentary Pharmacology & Therapeutics – 2016
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
Kagami T et al.
Alimentary Pharmacology & Therapeutics – 2020
Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)
Takeuchi T et al.
Digestion – 2018
Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database
Deguchi H et al.
Journal of Neurogastroenterology and Motility – 2018
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases
Oshima T, Miwa H.
Pharmacology & Therapeutics – 2016
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases
Inatomi et al.
Current Treatment Options in Gastroenterology – 2018
Potent Acid Suppression with PPIs and P-CABs: What’s New?
Hunt, R.H., Scarpignato, C.
Scientific Congresses
Food Effect on Vonoprazan
DDW – 2021
The Effect of Food on the Pharmacokinetics of the Potassium-competitive Acid Blocker Vonoprazan
Jenkins H, et al.
Treatment Practices in Patients Diagnosed with H. pylori Infection
DDW – 2021
Characterization of Treatment Practices for Patients with Newly Diagnosed H pylori Infection: A US Population-based Study Using Claims and Electronic Medical Record Data
Howden CW, et al.
*Vonoprazan is a product candidate that is under clinical study and that has not been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of vonoprazan.
The publications contained in this section are provided for informational purposes only. The information contained in each publication is accurate only as of the date it was originally issued and is not controlled by Phathom. Phathom assumes no responsibility for the information or statements in such publications and disavows any obligation to update the information contained in such publications after the date of their issuance.